Clinical Spectrum of Drug Hypersensitivity Reactions in Systemic Mastocytosis: Drug-Induced Anaphylaxis as a Unique Clinical Presentation
Medicina · 08.04.2026 · 62 (4) · 711
DOI: 10.3390/medicina62040711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicina, online erschienen am 08.04.2026. Verfasst von Eda Aslan und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Allergy and Immunology, Ege University Faculty of Medicine, Izmir 35100, Türkiye. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Anaphylaxis, Mastocytosis, Systemic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Systemic mastocytosis (SM) is a clonal mast cell disorder characterized by abnormal mast cell accumulation and activation in multiple organs, leading to mediator-related symptoms, including anaphylaxis. Drug hypersensitivity reactions (DHRs) are a major clinical challenge in SM, but their frequency and characteristics remain undefined. This study aimed to evaluate the frequency of drug allergy, identify high-risk drug groups, investigate reaction characteristics, and examine the relationship between drug reactions, baseline serum tryptase levels, and SM subtypes in patients with SM. Materials and Methods: We retrospectively analyzed 34 patients diagnosed with SM between 2009 and 2024 at Ege University Faculty of Medicine. Clinical features, SM subtypes, baseline serum tryptase levels, and DHR characteristics were recorded. Reactions to antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, anesthetics, radiocontrast media (RCM), and COVID-19 vaccines were graded using the Ring and Messmer anaphylaxis classification.
Results
Among 34 patients, the mean age was 48.6 ± 13.3 years, 53% were male, and 10 (29.4%) had DHRs. The most common culprit drugs were NSAIDs (17.6%) and β-lactam antibiotics (14.7%). Anaphylaxis was the predominant reaction, frequently associated with hypotension. In 5 patients (14.7%), drug-induced anaphylaxis was the initial and only manifestation of SM. No hypersensitivity reactions occurred to quinolones, general anesthetics, or COVID-19 vaccines. Median baseline tryptase was 50.25 µg/L (min–max: 8.59–200.00) overall, and 41.85 µg/L (min–max: 19.00–200.00) among those with DHRs.
Conclusions
Patients with SM are at increased risk of severe DHRs, particularly to NSAIDs and beta-lactam antibiotics. In some patients, drug allergy may be the first and only manifestation of SM. Measurement of baseline serum tryptase is essential in patients with drug-induced anaphylaxis. A comprehensive allergy assessment, including tolerance testing and individualized counseling, is crucial to ensure safe pharmacological management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Allergy and Immunology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.
- Department of Allergy and Immunology, Ordu University Training and Research Hospital, Ordu 52200, Türkiye.
- Department of Allergy and Immunology, Izmir City Hospital, Izmir 35540, Türkiye.
- Department of Allergy and Immunology, Osmaniye State Hospital, Osmaniye 80000, Türkiye.
- Department of Allergy and Immunology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir 35170, Türkiye.
- Department of Immunology and Allergy Diseases, Izmir Bakircay University Cigli Regional Training and Research Hospital, Izmir 35660, Türkiye.
ORCID-Profile: Ragıp Fatih Kural, Ümitcan Ateş, Züleyha Galata, Kutay Kırdök, Türkan Dizdar Canbaz, Gökten Bulut, Meryem Demir, Nur Soyer, Derya Demir, Aytül Zerrin Sin
Zitieren
APA
Aslan, E., Okan, K., Kural, R. F., İnan, S., Özeke, Y., Ateş, Ü., Yıldırım, O., Galata, Z., Kırdök, K., Ay, E., Dizdar Canbaz, T., Toksoy Şentürk, M. İ., Karaaslan Yetemen, S., Gümüşburun, R., Akten, H. S., Aytaç, H., Özışık, M., Çamyar, A., Demiroğlu, G., …, & Mete Gökmen, E. N. (2026). Clinical Spectrum of Drug Hypersensitivity Reactions in Systemic Mastocytosis: Drug-Induced Anaphylaxis as a Unique Clinical Presentation. Medicina, 62(4), 711. https://doi.org/10.3390/medicina62040711
Vancouver
Aslan E, Okan K, Kural RF, İnan S, Özeke Y, Ateş Ü, et al. Clinical Spectrum of Drug Hypersensitivity Reactions in Systemic Mastocytosis: Drug-Induced Anaphylaxis as a Unique Clinical Presentation. Medicina. 2026;62(4):711. doi:10.3390/medicina62040711
BibTeX
@article{Aslan2026,
author = {Aslan, Eda and Okan, Kasım and Kural, Ragıp Fatih and İnan, Sinem and Özeke, Yusuf and Ateş, Ümitcan and Yıldırım, Onurcan and Galata, Züleyha and Kırdök, Kutay and Ay, Ecem and Dizdar Canbaz, Türkan and Toksoy Şentürk, Meryem İrem and Karaaslan Yetemen, Seda and Gümüşburun, Reyhan and Akten, Hatice Serpil and Aytaç, Hasibe and Özışık, Melih and Çamyar, Asuman and Demiroğlu, Gülhan and Bulut, Gökten and Demir, Meryem and Soyer, Nur and Keklik Karadağ, Fatma and Demir, Derya and Hekimgil, Mine and Özsan, Nazan and Şarer Yürekli, Banu Pınar and Karaca, Emin and Durmaz, Mehmet Burak and Tunakan Dalgıç, Ceyda and Kokuludağ, Ali and Sin, Aytül Zerrin and Mete Gökmen, Emine Nihal},
title = {Clinical Spectrum of Drug Hypersensitivity Reactions in Systemic Mastocytosis: Drug-Induced Anaphylaxis as a Unique Clinical Presentation},
journal = {Medicina},
year = {2026},
volume = {62},
number = {4},
pages = {711},
doi = {10.3390/medicina62040711}
}
EUVIMED